Skip to main content
Equibles
ANIP logo

ANIP · Ani Pharmaceuticals Inc · Webcasts, Transcripts & Audio

Track ANIP — free

Use ANIP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANIP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$72.61 -1.14 (-1.55%) At close · Oct 23
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.67B
Shares
22.97M
Volume · Oct 23 318.61K Avg daily vol (3M) 382.32K

Ani Pharmaceuticals Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Ani Pharmaceuticals Inc (ANIP), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-09-15
Ani Pharmaceuticals Inc (ANIP) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Ani Pharmaceuticals Inc (ANIP) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-10
Ani Pharmaceuticals Inc (ANIP) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-07
Ani Pharmaceuticals Inc (ANIP) Q2 2026 Earnings Call Transcript
Confident tone 2026 guidance and outlook Illuvian and ophthalmology opportunity Sales force expansion
Revenue
$266.04M
▲ 25.9% YoY
Diluted EPS
$1.05
▲ 191.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Ani Pharmaceuticals Inc (ANIP) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-08
Ani Pharmaceuticals Inc (ANIP) Q1 2026 Earnings Call Transcript
Confident tone Rare Disease Transformation / Cortrophin Gel Capital Allocation / Share Repurchase / Business Development Q1 Operational Headwinds / Insurance Re-verifications
Revenue
$237.46M
▲ 20.5% YoY
Diluted EPS
$1.28
▲ 85.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-27
Ani Pharmaceuticals Inc (ANIP) Q4 2025 Earnings Call Transcript
Confident tone Cortrophin rare disease growth Acute gouty arthritis expansion ILUVIEN commercial turnaround
Revenue
$247.06M*
▲ 29.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-07
Ani Pharmaceuticals Inc (ANIP) Q3 2025 Earnings Call Transcript
Confident tone Cortrophin Gel Growth ILUVIEN / Retina Reset Sales Force Expansion
Revenue
$227.81M
▲ 53.6% YoY
Diluted EPS
$1.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-08
Ani Pharmaceuticals Inc (ANIP) Q2 2025 Earnings Call Transcript
Confident tone Rare Disease / Cortrophin Gel growth NEW DAY clinical trial Ophthalmology / revenue synergies
Revenue
$211.37M
▲ 53.1% YoY
Diluted EPS
$0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Ani Pharmaceuticals Inc (ANIP) Q1 2025 Earnings Call Transcript
Confident tone Retina (ILUVIEN/YUTIQ) near-term challenges Royalty buyout on ILUVIEN/YUTIQ Cortrophin Gel growth and outlook
Revenue
$197.12M
▲ 43.4% YoY
Diluted EPS
$0.69
▼ 15.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-28
Ani Pharmaceuticals Inc (ANIP) Q4 2024 Earnings Call Transcript
Confident tone Cortrophin Gel growth Alimera acquisition / ophthalmology franchise Rare Disease franchise expansion
Revenue
$190.57M*
▲ 44.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-20
Ani Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Transcript
Confident tone Alimera acquisition and integration Cortrophin Gel growth Rare Disease segment outlook
Revenue
$148.33M
▲ 12.5% YoY
Diluted EPS
$-1.27
▼ 382.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Ani Pharmaceuticals Inc (ANIP) Q2 2024 Earnings Call Transcript
Confident tone Rare disease / Cortrophin gel growth Competitive landscape (ACTH category) Alimera Sciences acquisition
Revenue
$138.04M
▲ 18.4% YoY
Diluted EPS
$-0.14
▼ 148.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-17
Ani Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript
Confident tone Cortrophin Gel commercial momentum Rare disease business expansion and M&A Financial guidance reiteration
Revenue
$137.43M
▲ 28.7% YoY
Diluted EPS
$0.82
▲ 1266.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Ani Pharmaceuticals Inc (ANIP) Q4 2023 Earnings Call Transcript
Confident tone Therapeutic area expansion Cortrophin Gel franchise growth Financial results and 2024 guidance
Revenue
$131.65M*
▲ 39.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-15
Ani Pharmaceuticals Inc (ANIP) Q3 2023 Earnings Call Transcript
Revenue
$131.83M
▲ 57.3% YoY
Diluted EPS
$0.45
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-09-07
Ani Pharmaceuticals Inc (ANIP) Q2 2023 Earnings Call Transcript
Revenue
$116.55M
▲ 57.8% YoY
Diluted EPS
$0.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-06-09
Ani Pharmaceuticals Inc (ANIP) Q1 2023 Earnings Call Transcript
Revenue
$106.79M
▲ 65.6% YoY
Diluted EPS
$0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Ani Pharmaceuticals Inc (ANIP) Q4 2022 Earnings Call Transcript
Revenue
$94.23M*
▲ 54.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Ani Pharmaceuticals Inc (ANIP) Q3 2022 Earnings Call Transcript
Revenue
$83.82M
▲ 61% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Ani Pharmaceuticals Inc (ANIP) Q2 2022 Earnings Call Transcript
Revenue
$73.86M
▲ 51.9% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Ani Pharmaceuticals Inc (ANIP) Q1 2022 Earnings Call Transcript
Revenue
$64.48M
▲ 18.3% YoY
Diluted EPS
$-1.27
▼ 12800% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-15
Ani Pharmaceuticals Inc (ANIP) Q4 2021 Earnings Call Transcript
Revenue
$60.93M*
▲ 6.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-01
Ani Pharmaceuticals Inc (ANIP) Q3 2021 Earnings Call Transcript
Revenue
$52.06M
▼ 1.7% YoY
Diluted EPS
$-0.37
▼ 1025% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-06
Ani Pharmaceuticals Inc (ANIP) Q2 2021 Earnings Call Transcript
Revenue
$48.62M
▲ 0.3% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-07
Ani Pharmaceuticals Inc (ANIP) Q1 2021 Earnings Call Transcript
Revenue
$54.52M
▲ 9.5% YoY
Diluted EPS
$0.01
Gross margin
63.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Ani Pharmaceuticals Inc (ANIP) Q4 2020 Earnings Call Transcript
Revenue
$57.25M
▲ 19.4% YoY
Diluted EPS
$-0.30
Gross margin
57.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ani Pharmaceuticals Inc (ANIP) Q3 2020 Earnings Call Transcript
Revenue
$52.98M
▲ 3.2% YoY
Diluted EPS
$0.04
▼ 87.5% YoY
Gross margin
62.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Ani Pharmaceuticals Inc (ANIP) Q2 2020 Earnings Call Transcript
Revenue
$48.47M
▼ 10.8% YoY
Diluted EPS
$-1.03
▼ 294.3% YoY
Gross margin
57.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Ani Pharmaceuticals Inc (ANIP) Q1 2020 Earnings Call Transcript
Revenue
$49.77M
▼ 5.9% YoY
Diluted EPS
$-0.59
▼ 1575% YoY
Gross margin
56.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Ani Pharmaceuticals Inc (ANIP) Q4 2019 Earnings Call
Revenue
$47.97M
▼ 16% YoY
Diluted EPS
$-0.41
▼ 189.1% YoY
Gross margin
62.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–31 of 31 webcasts
Key facts CIK 1023024 CUSIP 00182C103 13F (30d) 39 filings 39 filers Visit website Investor relations